Endpoint 5: Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 2, 8, 12, 16 and Statistical Analysis

Statistical analysis title	ACR50 Week 2: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo vs. Placebo/Placebo/Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.873
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 2: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.134
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 2: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority

Statistical analysis title	ACR50 Week 2: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.532
Method	Cochran-Mantel-Haenszel

Statistical analysis title	ACR50 Week 8: SBI-087/ Placebo/ Placebo
P-value	= 0.502
Method	Cochran-Mantel-Haenszel

Comparison groups	SBI-087/ Placebo/ Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.731
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 8: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.355
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 8: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.629
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 8: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.36

Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 12: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.094
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 12: SBI-087/ SBI-087/ Placebo

Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.005
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 12: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.06
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 12: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.209
Method	Cochran-Mantel-Haenszel

Statistical analysis title	ACR50 Week 16: SBI-087/ Placebo/ Placebo
Comparison groups	SBI-087/ Placebo/ Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.604
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 16: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.497
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 16: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087

Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.707
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 16: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.206
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 24: SBI-087/ Placebo/ Placebo

Comparison groups	SBI-087/ Placebo/ Placebo
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.663
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 24: SBI-087/ SBI-087/ Placebo
Comparison groups	SBI-087/ SBI-087/ Placebo
Number of subjects included in analysis	42
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.471
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 24: SBI-087/ Placebo/ SBI-087
Comparison groups	SBI-087/ Placebo/ SBI-087
Number of subjects included in analysis	43
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.656
Method	Cochran-Mantel-Haenszel
Statistical analysis title	ACR50 Week 24: SBI-087/ SBI-087/ SBI-087
Comparison groups	SBI-087/ SBI-087/ SBI-087
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.203
Method	Cochran-Mantel-Haenszel